OHR Pharmaceutical Inc.

Financials

v3.8.0.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2018
Sep. 30, 2017
CURRENT ASSETS    
Cash $ 5,215,247 $ 12,801,085
Prepaid expenses and other current assets 622,184 223,278
Total Current Assets 5,837,431 13,024,363
EQUIPMENT, net 20,448 63,757
OTHER ASSETS    
Security deposit   12,243
Intangible assets, net 13,529,626 14,087,602
Goodwill   740,912
TOTAL ASSETS 19,387,505 27,928,877
CURRENT LIABILITIES    
Accounts payable and accrued expenses 1,444,465 4,827,525
Notes payable 287,902 106,387
Total Current Liabilities 1,732,367 4,933,912
Long-term liabilities   150,000
TOTAL LIABILITIES 1,732,367 5,083,912
STOCKHOLDERS' EQUITY    
Preferred stock, Series B; 6,000,000 shares authorized, $0.0001 par value, 0 shares issued and outstanding, respectively  
Common stock; 180,000,000 shares authorized, $0.0001 par value, 56,466,428 and 56,196,428 shares issued and outstanding, respectively 5,647 5,619
Additional paid-in capital 132,074,223 130,927,953
Accumulated deficit (114,424,732) (108,088,607)
Total Stockholders' Equity 17,655,138 22,844,965
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 19,387,505 $ 27,928,877
v3.8.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
OPERATING EXPENSES        
General and administrative $ 591,184 $ 1,404,061 $ 2,101,216 $ 3,150,417
Research and development 1,801,946 5,993,928 4,189,677 10,925,072
Depreciation and amortization 278,525 291,875 563,511 590,310
Loss on impairment of goodwill 740,912   740,912  
Gain on settlement of liabilities (1,228,805)   (1,228,805)  
OPERATING LOSS 2,183,762 7,689,864 6,366,511 14,665,799
OTHER INCOME (EXPENSE)        
Other income (expense) (17,814)   (17,799)  
Interest income (expense), net 16,809 (208) 48,185 73
Total Other Income (Expense) (1,005) (208) 30,386 73
LOSS FROM OPERATIONS (2,184,767) (7,690,072) (6,336,125) (14,665,726)
NET LOSS $ (2,184,767) $ (7,690,072) $ (6,336,125) $ (14,665,726)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share) $ (0.04) $ (0.21) $ (0.11) $ (0.43)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:        
BASIC AND DILUTED (in shares) 56,464,984 36,738,396 56,332,939 34,381,781
v3.8.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2018
Mar. 31, 2018
Mar. 31, 2017
OPERATING ACTIVITIES      
Net loss $ (2,184,767) $ (6,336,125) $ (14,665,726)
Adjustments to reconcile net loss to net cash used by operating activities:      
Common stock issued for services   145,301 633,697
Stock option expense   730,997 846,270
Depreciation   5,535 31,060
Amortization of intangible assets 275,857 557,976 559,250
Gain on settlement of liabilities   1,228,805  
Loss on sale of property and equipment   17,814  
Loss on impairment of goodwill 740,912 740,912  
Changes in operating assets and liabilities      
Prepaid expenses and other current assets   (43,609) 310,429
Accounts payable and accrued expenses   (4,761,865) 2,386,713
Net Cash Used in Operating Activities   (7,714,259) (9,898,307)
INVESTING ACTIVITIES      
Purchase of property and equipment     (4,833)
Net Cash Provided by/ (Used in) Investing Activities     (4,833)
FINANCING ACTIVITIES      
Proceeds for issuance of common stock for cash     6,846,483
Proceeds from warrants exercised for cash   270,000 118,801
Repayments of short-term notes payable   (141,579) (87,798)
Net Cash Provided by/ (Used in) Financing Activities   128,421 6,877,486
NET CHANGE IN CASH   (7,585,838) (3,025,654)
CASH AT BEGINNING OF PERIOD   12,801,085 12,546,890
CASH AT END OF PERIOD $ 5,215,247 5,215,247 9,521,236
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION CASH PAID FOR:      
Interest   2,899 798
Income Taxes    
NON CASH FINANCING ACTIVITIES:      
Financing of insurance premiums through issuance of short term notes   $ 323,094 $ 261,326